Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
779 results about "Osteo arthritis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
System and method for building and manipulating a centralized measurement value database
InactiveUS20020186818A1Low penetrationEasy to aimImage enhancementImage analysisMarket penetrationEfficacy
A system and method for building and / or manipulating a centralized medical image quantitative information database aid in diagnosing diseases, identifying prevalence of diseases, and analyzing market penetration data and efficacy of different drugs. In one embodiment, the diseases are bone-related, such as osteoporosis and osteoarthritis. Subjects' medical images, personal and treatment information are obtained at information collection terminals, for example, at medical and / or dental facilities, and are transferred to a central database, either directly or through a system server. Quantitative information is derived from the medical images, and stored in a central database, associated with subjects' personal and treatment information. Authorized users, such as medical officials and / or pharmaceutical companies, can access the database, either directly or through the central server, to diagnose diseases and perform statistical analysis on the stored data. Decisions can be made regarding marketing of drugs for treating the diseases in question, based on analysis of efficacy, market penetration, and performance of competitive drugs.
Owner:IMAGING THERAPEUTICS +1
Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent
The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the COX-2 and 5-LO pathways. The present invention further provides a novel method for simultaneously inhibiting the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) enzymes, and reducing cox-2 mRNA production. Finally, the present invention includes a method for weight loss and blood glucose control. The methods of this invention are comprised of administering to a host in need thereof an effective amount of the composition of this invention together with a pharmaceutically acceptable carrier. This invention relates generally to the prevention and treatment of diseases and conditions mediated by the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) pathways, including but not limited to the relief joint discomfort and pain associated with conditions such as osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse.
Owner:UNIGEN
Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee
InactiveUS7022506B2Heart defibrillatorsMagnetotherapy using coils/electromagnetsHuman useCells transplantation
A method of determining the voltage and current output required for the application of specific and selective electric and electromagnetic signals to diseased articular cartilage in the treatment of osteoarthritis, cartilage defects due to trauma or sports injury, or used as an adjunct with other therapies (cell transplantation, tissue-engineered scaffolds, growth factors, etc.) for treating cartilage defects in the human knee joint and a device for delivering such signals to a patient's knee. An analytical model of the human knee is developed whereby the total tissue volume in the human knee may be determined for comparison to the total tissue volume of the diseased tissue in the animal model using electric field and current density histograms. The voltage and current output used in the animal model is scaled based on the ratio of the total tissue volume of the diseased tissue of the human to the total tissue volume of the diseased tissue in the animal model and the resulting field is applied to the diseased tissue of the human using at least two electrodes applied to the knee or a coil or solenoid placed around the knee. The voltage of the signal applied to the electrodes, coil or solenoid is varied based on the size of the knee joint; larger knee joints require larger voltages to generate the effective electric field.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS
Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions / disorders / diseases due to mutations or dysregulation of the Wnt pathway and / or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
Owner:BIOSPLICE THERAPEUTICS INC
1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
![1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof](https://images-eureka.patsnap.com/patent_img/ab7b9af2-18c0-4461-a0e2-7121e6fc6aba/US08618128-20131231-C00001.png "1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof")
![1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof](https://images-eureka.patsnap.com/patent_img/ab7b9af2-18c0-4461-a0e2-7121e6fc6aba/US08618128-20131231-C00002.png "1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof")
![1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof](https://images-eureka.patsnap.com/patent_img/ab7b9af2-18c0-4461-a0e2-7121e6fc6aba/US08618128-20131231-C00003.png "1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof")
Owner:BIOSPLICE THERAPEUTICS INC
Osteo-arthritis knee brace
InactiveUS6875187B2Simple treatmentCorrection of leg curvatureNon-surgical orthopedic devicesOsteoarthritic kneeKnee Joint
A knee brace including a lateral hinge component and a medial hinge component, a lower member encompassable about a lower leg portion and having a lateral element and a medical element each extending upwardly and connectingly engaged respectively to the hinge components, an upper member encompassable about an upper leg portion and having a lateral element extending downwardly and connectingly engaged to the lateral hinge component and a medial element extending downwardly to a distal end terminating above the medial hinge component. The distal end has a configuration non-obstructingly complementarity to an upper shape of the medial hinge component for full and uninterrupted flexion of the lower leg at the knee joint. A medially disposed arm is connectingly engaged to the medial hinge component and extends upwardly from the hinge component to be adjacent the medial element of the upper member for connection to each other with a releasably securable slidable engager. The arm and medial element are slidable and securable against each other to thereby laterally inwardly and outwardly position the upper member in angular relationship to the lower member and consequently treat inward or outward leg curvature through correction of knee joint orientation.
Owner:OSSUR HF
Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
Owner:AMGEN INC
Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee
InactiveUS20060190043A1ElectrotherapyMagnetotherapy using coils/electromagnetsHuman useArticular cartilage
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Il-21 antagonists
InactiveUS20070122413A1Increasing in vivo serum half-lifeModulate antibody responseNervous disorderAntibody mimetics/scaffoldsAutoimmune conditionAutoimmune disease
Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
Owner:ZYMOGENETICS INC
Arthritis-associated protein
Disclosed are methods and compositions for early diagnosis, monitoring and treatment of cartilage degenerative conditions, including forms of arthritis. In particular, the invention relates to a protein, termed “adlican,” that is differentially transcribed and expressed in human subjects suffering from arthritis, such as osteoarthritis (OA) and rheumatoid arthritis (RA) compared with non-arthritis sufferers, antibodies which recognize this protein, and methods for diagnosing arthritis.
Owner:NOVARTIS AG
Apoptosis inducing molecule II and methods of use
The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.
Owner:HUMAN GENOME SCI INC
Osteoarthritis knee orthosis
ActiveUS20090259154A1Easy to manage and controlEasy to makeRestraining devicesNon-surgical orthopedic devicesKnee orthosisThigh musculature
An osteoarthritis knee brace for treating a patient's knee joint, a surrounding area thereof, and the upper and lower leg portions. The knee brace has at least one vertical strut with upper and lower portions, at least one pivoting hinge intermediately disposed there between, a shin cuff attached to the vertical strut lower portion and positioned below the hinge and a thigh cuff attached to the vertical strut upper portion and positioned above the hinge. The brace further includes a means for applying a corrective and therapeutic force to the osteoarthritis damaged knee joint and all of the surrounding areas including the upper and lower leg portions, which are removeably positionable about the osteoarthritis knee brace. Still further, the brace include a means for equally distributing the corrective and therapeutic force at each point at which the means for applying a corrective and therapeutic force is applied.
Owner:NACE RICHARD NACE
Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM
InactiveUS7465445B2Modulate productionPrevent diseaseOrganic active ingredientsBiocideAntigenTherapeutic effect
An antibody against AILIM (alternatively called JTT-1 antigen, JTT-2 antigen, ICOS and 8F4) was found to have a significant therapeutic effect on arthrosis, for example, rheumatoid arthritis and osteoarthritis, graft versus host disease, graft immune rejection, inflammation (hepatitis and inflammatory bowel diseases), diseased condition accompanied by the excessive production of an antibody against a foreign antigen triggered by immunological sensitization by the antigen.
Owner:JAPAN TOBACCO INC
Method of Treating Osteoarthritis with an Antibody to NGF
Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
Owner:REGENERON PHARM INC
Substituted heterocyclic compounds and methods of use
The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
Owner:AMGEN INC
Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip
A method of determining the voltage and current required for the application of specific and selective electric and electromagnetic signals to diseased articular cartilage in the treatment of osteoarthritis, cartilage defects due to trauma or sports injury, or used as an adjunct with other therapies (cell transplantation, tissue-engineered scaffold, growth factors, etc.) for treating cartilage defects in the human hip joint and a device for delivering such signals to a patient's hip. Anatomic, analytical, and planar circuit models are developed to determining the impedances, conductivities, and current flows in the human hip joint and its surrounding soft tissues and skin that are required to produce a 20 mV / cm electric field in the synovium and articular cartilage of the human hip. The voltage of the signal applied to the surface electrodes or to a coil(s) or solenoid is varied based on the size of the hip joint; larger hip joints require larger voltages to generate the effective electric field.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Compositions and methods for the treatment of arthritis
The present invention provides compositions, combination of medicaments, and methods for the treatment of certain conditions such as arthritis, and in particular, reactive arthritis, osteoarthritis, and bursitis, among others.
Owner:BONNER ERNEST L JR +1
Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals
Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and / or degenerative diseases, disorders, conditions, and processes in humans and other animals. In one embodiment, the compositions include at least 4 of the following: a MMP1 inhibitor, a MMP2 inhibitor, a MMP3 inhibitor, a MMP7 inhibitor, a MMP9 inhibitor, an ADAMTS-4 inhibitor, a MMP13 inhibitor, and a MMP14 inhibitor. In another embodiment, the compositions include a curcuminoid, a polymethoxylated flavone, a catechin, and a boswellic acid.
Owner:BAKER DONALD J
Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals
Methods and devices for the regulation of matrix metalloproteinase gene expression in cartilage cells via the application of fields generated by specific and selective electric and electromagnetic signals in the treatment of diseased or injured articular cartilage. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased cartilage tissue that include generating specific and selective electric and electromagnetic signals that generate fields optimized for reduction of matrix metalloproteinase gene expression and exposing cartilage tissue to the fields generated by specific and selective signals so as to regulate matrix metalloproteinase gene expression in such cartilage tissue. The resulting methods and devices are useful for the targeted treatment of osteoarthritis, rheumatoid arthritis, cartilage injury, cartilage defects, and tumor metastasis.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Methods for using JNK inhibitors for treating or preventing disease-related wasting
InactiveUS20040034084A1Inhibit progressPrevent worseningAntibacterial agentsBiocideChronic inflammatory diseaseKidney Failures
The present invention relates to methods useful for the treatment or prevention of disease-related wasting. The methods of the invention comprise the administration of an effective amount of a JNK Inhibitor. In one embodiment, the disease is HIV, AIDS, cancer, end-stage renal disease, kidney failure, chronic heart disease, obstructive pulmonary disease or tuberculosis. The methods can further comprise the administration of a therapeutic or prophylactic agent useful for the treatment or prevention of HIV, AIDS, cancer, end-stage renal disease, kidney failure, chronic heart disease, obstructive pulmonary disease, chronic infectious diseases (e.g., osteoarthritis and bacterial endocarditis), chronic inflammatory diseases (e.g., scleroderma and mixed connective tissue disease) or tuberculosis.
Owner:CELGENE CORP
Method for treating osteoarthritis by stem cells and composition
ActiveCN105796600ADoes not impair activityImprove survival rateAntipyreticAnalgesicsMedicineMesenchymal stem cell
The invention relates to a method for treating osteoarthritis by stem cells and a composition. Particularly, the invention relates to a cell treatment composition for treating osteoarthritis and cartilage defects. The composition includes mesenchyma stem cells, hyaluronic acid or pharmaceutical salt, sodium chloride and water. The invention also relates to a method for preparing the composition. The cell treatment composition has the excellent properties.
Owner:BOYALIFE
Nutraceuticals for the treatment, protection and restoration of connective tissues
InactiveUS20050020500A1Smooth connectionIncrease blood flowOrganic active ingredientsPeptide/protein ingredientsMultiple formsConnective tissue fiber
The invention relates to a method for isolating from connective tissue a variety of glycosminoglycan (GAG)-polypeptide complexes and polypeptides which are substantially free of contaminating DNA and other molecules such as viruses which may be associated with the DNA in the cell. The invention also relates to uses of GAG-peptide complexes and polypeptides substantially free of DNA either directly, or after further processing, for the treatment, protection and restoration of connective tissues in inflammatory and degenerative disorders such as rheumatoid arthritis and osteoarthritis in any of their multiple forms or other degenerative conditions in mammals.
Owner:INST OF NUTRACEUTICAL RES
Endoxifen methods and compositions in the treatment of mammalian diseases
InactiveUS20120164075A1Particular effectivenessAntibacterial agentsOrganic active ingredientsFertility DisordersLiposome
The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases, infectious diseases, fertility disorders, osteoporosis, osteoarthritis, and / or cardiovascular diseases. Specifically, the present invention relates to compositions comprising endoxifen for use in the treatment of such disorders or predisposition to such disorders, for use in manufacture of medicaments for treating such disorders, and methods comprising use of such compositions in such treatments.
Owner:JINA PHARMA
Novel anthranilic acid derivative or salt thereof
The anthranilic acid derivative or the salt thereof represented by the general formulawherein R1 and R2 are hydrogen atom, or the like; R3 is a phenyl, cycloalkyl or bicyclic heterocyclic group which may be substituted, or the like; R4 is a phenyl, cycloalkyl or pyridyl group which may be substituted, or the like; X1 is an alkylene or alkenylene group which may be substituted or a bond; X2 is the general formula -X3-X4- or -X4-X3-, wherein X3 is a sulfur atom, an imino group or a bond, or the like; X4 means an alkylene or alkenylene group which may be substituted or a bond; is useful for a remedy such as rheumatoid arthritis, osteoarthritis and carcinoma, because it shows MMP-13 production inhibitory effect.
Owner:TOYAMA CHEM CO LTD
Human aggrecanase and nucleic acid compositions encoding the same
Human aggrecanase and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting aggrecanase activity in a host and methods of treating disease conditions associated with aggrecanase activity, e.g. rheumatoid arthritis, osteo-arthritis, infectious arthritis, gouty arthritis, psoriatic arthritis, spondolysis, sports injury, joint trauma, pulmonary disease, fibrosis, and the like.
Owner:SYNTEX (USA) INC
Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof
InactiveCN104188999APromote absorptionFacilitate depositionHydroxy compound active ingredientsPeptide/protein ingredientsPainful jointsIncreased Bone Density
The invention discloses a composition capable of increasing bone density and improving functions of skeletons and joints and a preparation method thereof. The composition capable of increasing the bone density and improving the functions of the skeletons and joints comprises the following main components in parts by mass: 1-400 parts of glucosamine, 1-400 parts of chondroitin sulfate, 1-400 parts of calcium medicinal preparation, 0.0001-1 part of vitamin D and 0.0001-1 part of vitamin K. The composition capable of increasing the bone density and improving the functions of the skeletons and joints has the beneficial effects that calcium is supplemented for young and old patients suffering from osteoporosis, absorption and deposition of calcium in skeleton are promoted, the bone density is effectively increased, and syndromes such as osteoarthritis and bone and arthrosis pain are also alleviated.
Owner:哈药集团制药六厂
Condensed Imidazole Compound And Use Thereof
InactiveUS20080167314A1Maintain good propertiesBiocideSenses disorderVascular diseaseAutoimmune disease
The present invention relates to a compound represented by the formula [I]wherein X1, X2 and X3 are each an optionally substituted CH or a nitrogen atom, and any one of X1, X2 and X3 is a nitrogen atom, X4 is an optionally substituted CH, R1 is an optionally substituted phenyl group or an optionally substituted heterocyclic group, and R2 is an optionally substituted pyridin-4-yl group, an optionally substituted pyridine-N-oxide-4-yl group or an optionally substituted pyrimidin-4-yl group, or a salt thereof. The compound has superior p38 MAP kinase inhibitory activity and MMP-13 production inhibitory activity, and is useful as an agent for the prophylaxis or treatment and the like of an inflammatory disease, an autoimmune disease, a debilitating disease, an osteoarticular degenerative disease, a neurodegenerative disease, a vascular disease, a neoplastic disease or an infectious disease.
Owner:TAKEDA PHARMA CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com